PEDRO PIEDRA to Vaccination
This is a "connection" page, showing publications PEDRO PIEDRA has written about Vaccination.
Connection Strength
0.635
-
Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J. 2000 Aug; 19(8):805-8; discussion 809-10.
Score: 0.113
-
Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
Score: 0.083
-
Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996 Jan; 15(1):23-31.
Score: 0.083
-
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
Score: 0.071
-
Sustained Within-season Vaccine Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New Vaccine Surveillance Network, 2015-2016 Through 2019-2020. Clin Infect Dis. 2023 02 08; 76(3):e1031-e1039.
Score: 0.034
-
Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J. 2003 Feb; 22(2 Suppl):S94-9.
Score: 0.034
-
Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin Pediatr Infect Dis. 2002 Apr; 13(2):90-6.
Score: 0.032
-
Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021 07 05; 39(30):4063-4071.
Score: 0.030
-
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
Score: 0.028
-
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb; 136(2):168-75.
Score: 0.027
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
Score: 0.025
-
Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J. 1998 Mar; 17(3):217-24.
Score: 0.024
-
Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Respir Infect. 1995 Dec; 10(4):216-23.
Score: 0.021
-
Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
Score: 0.009
-
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
Score: 0.009
-
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000 Mar; 181(3):1133-7.
Score: 0.007
-
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis. 1996 Jun; 173(6):1313-9.
Score: 0.005